Other Definitions
naltrexone (dict)

Naltrexone

bgcolor="#ffffff" align="center" colspan="2" |
align="center" colspan="2" | 17-(cyclopropylmethyl)-4,5α-epoxy-
3,14-dihydroxymorphinan-6-one
CAS number
16676-29-2 (HCl)
ATC code
?
bgcolor="#eeeeee" | Chemical formula bgcolor="#ddeeff" | C20H23NO4
bgcolor="#eeeeee" | Molecular weight bgcolor="#ddeeff" | 341.4
bgcolor="#eeeeee" | Bioavailability bgcolor="#ddeeff" | 5-40%
bgcolor="#eeeeee" | Metabolism bgcolor="#ddeeff" | hepatic
bgcolor="#eeeeee" | Elimination half-life bgcolor="#ddeeff" | 4 hours (naltrexone),
13 hours (6-β-naltrexol)
bgcolor="#eeeeee" | Excretion bgcolor="#ddeeff" | renal
bgcolor="#eeeeee" | Pregnancy category bgcolor="#ddeeff" | Category B3 (Australia)
bgcolor="#eeeeee" | Legal status bgcolor="#ddeeff" | Schedule 4 (Australia)
bgcolor="#eeeeee" | Routes of administration bgcolor="#ddeeff" | oral
Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence and opioid dependence. It is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade name Revia.

Pharmacology

Naltrexone, and its active metabolite 6-β-naltrexol, are competitive antagonists at μ- and κ-opioid receptors, and to a lesser extent at δ-opioid receptors. This blockade of opioid receptors is the basis behind its action in the management of opioid dependence—it reversibly blocks or attenuates the effects of opioids. Its use in alcohol (ethanol) dependence has been studied and has been shown to be effective. Its mechanism of action in this indication is not fully understood, but as an opioid-receptor antagonist is likely to be due to the modulation of the dopaminergic mesolimbic pathway which ethanol is believed to activate.

Rapid detoxification

Naltrexone is sometimes used for rapid detoxification ("rapid detox") regimens for opioid dependence. The principle of rapid detoxification is to induce opioid-receptor blockade while the patient is in a state of impaired consciousness so as to attenuate the withdrawal symptoms experienced by the patient. Rapid detoxification under general anaesthesia involves an unconscious patient and requires intubation and external ventilation. Rapid detoxification is also possible under sedation. The rapid detoxification procedure is followed by oral naltrexone daily for up to 12 months for opioid dependence management. Rapid detoxification has been criticised by some for its questionable efficacy in long-term opioid dependence management. Rapid detoxification has often been misrepresented as a one-off "cure" for opioid dependence, when it is only intended as the initial step in an overall management regimen. Rapid detoxification is effective for short-term opioid detoxification, but is approximately 10 times more expensive than conventional detoxification procedures.

Safety

There has been some controversy regarding the use of opioid-receptor antagonists, such as naltrexone, in the long-term management of opioid dependence due to the effect of these agents in sensitising the opioid receptors. That is, after therapy, the opioid receptors continue to have increased sensitivity for a period during which the patient is at increased risk of opioid overdose. This effect reinforces the necessity of monitoring of therapy and provision of patient support measures by medical practitioners.

 

<< PreviousWord BrowserNext >>
ray mears
homo georgicus
toward the within
papaverine
john forbes robertson
space pen
petrov's defence
uss john adams (1799)
the wall (disambiguation)
nguyen binh khiem
peanut oil
live bootleg
mastermind productions
thomas pride (vc)
exchange sacrifice
mohammad hashim kamali
gwin
calshot
steve barton
freeppp
yogi pullavar
sonic origami
hugh talbot burgoyne
downy mildew
undercity
buhl
order of aviz
granny boswell
mastermind media
2001 in australia
hotel canberra
inner north coast ranges
john edmund commerell
council of troyes
aradia de toscano
best off sky ranger
interactive geometry software
barry mazur
kano motonobu
car wash
hagerstown suns
rock in a hard place
kingsport mets
village vanguard